Search for: "McNeil v. Commissioner of Correction" Results 1 - 7 of 7
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
14 Jun 2021, 10:31 am by Eric Goldman
Amicus brief from IP/Internet/Antitrust professors. * FTC opinions: majority by Commissioner Simons, concurrence by Commissioner Slaughter, dissent by Commissioner Phillips. [read post]
3 Mar 2010, 5:05 am
‘The solution lies in resources’ says FDA Commissioner Hamburg (FDA Law Blog)   Products Actoplus MET (Pioglitazone) – US: Takeda files patent infringement suit against Aurobindo following Para IV certification as part of ANDA to manufacture generic Actoplus MET (Patent Docs) Advair diskus (Fluticasone, Salmeterol) – US: PTO denies PTE for Advair diskus patent; Office again clarifies that PTEs are not availabile for ‘synergistic combinations’… [read post]
3 Mar 2010, 5:05 am
‘The solution lies in resources’ says FDA Commissioner Hamburg (FDA Law Blog)   Products Actoplus MET (Pioglitazone) – US: Takeda files patent infringement suit against Aurobindo following Para IV certification as part of ANDA to manufacture generic Actoplus MET (Patent Docs) Advair diskus (Fluticasone, Salmeterol) – US: PTO denies PTE for Advair diskus patent; Office again clarifies that PTEs are not availabile for ‘synergistic combinations’… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
25 Jan 2008, 1:00 am
: (Generic Pharmaceuticals & IP),Arava (Leflunomide) - Sanofi-Aventis loses bid to dismiss Louisiana Wholsesale Drug Co's antitrust claims accusing S-A of unlawfully blocking generic competition for Arava by filing a sham Citizen Petition with the USFDA: (IP Law360),Ciprofloxacin - CIPLA issued notice by National Pharmaceutical Pricing Authority for allegedly overpricing its antibiotic Ciprofloxacin (especially of note because CIPLA is objecting… [read post]